van Boven, Job Fm <br/><br/>
Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.  [electronic resource] 

 -  International journal of chronic obstructive pulmonary disease  2016 
 - 2191-2201 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1178-2005 
<br/><br/><label>Standard No.: </label>10.2147/COPD.S114738  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic beta-2 Receptor Agonists--economics<br/>Aged<br/>Benzoxazines--economics<br/>Bronchodilator Agents--economics<br/>Budgets<br/>Cholinergic Antagonists--economics<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Drug Combinations<br/>Drug Costs<br/>Female<br/>Forced Expiratory Volume<br/>Humans<br/>Lung--drug effects<br/>Male<br/>Markov Chains<br/>Medication Adherence<br/>Middle Aged<br/>Models, Economic<br/>Netherlands<br/>Pulmonary Disease, Chronic Obstructive--drug therapy<br/>Quality-Adjusted Life Years<br/>Severity of Illness Index<br/>Time Factors<br/>Tiotropium Bromide--economics<br/>Treatment Outcome